Cangene edges down on stopped Phase II

Cangene (TSE:CNJ) was off C$0.15 to C$6.60 on Friday after reporting post-market on Thursday that it stopped a pilot Phase II trial of its anti-hepatitis C virus (HCV) hyperimmune globulin treatment i...